PTPRC and neoplasm: Critically, CDDO-Me reverted the immunosuppressive phenotype of the tumor microenvironment in all tumor genotypes, decreasing macrophage infiltration (9.6–12% of CD45+ cells; Figure 4A), CD206 expression (34–41% reduction; Figure 4B), and PD-L1 levels (21–26% reduction; Figure 4C).